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The U.S. Centers for Disease Control and Prevention define a traumatic brain injury (TBI) as being caused by a bump, blow, or jolt to the head or a penetrating head injury that disrupts normal brain function ([www.cdc.gov/traumaticbraininjury/data](www.cdc.gov/traumaticbraininjury/data)). The causes of TBI are extremely diverse, ranging from accidents on the highways, to involvement in sports related injuries, and the effects of improvised explosive devices in the theater of war. Falls are the major cause of TBI in children and the elderly (Blennow et al., 2016). TBI causes neurobehavioral deficits, especially in motor and cognitive functions (Langlois et al., 2006). The observed cognitive changes that follow TBI include decreased mental flexibility, impaired attention, poor planning/judgment, deficits in verbal fluency, dementia, and problems with working memory (Levin and Kraus, 1994; Johnson et al., 2010). Furthermore, TBI is associated with significant morbidity/mortality, pain, and fatigue (Levin and Diaz-Arrastia, 2015; Blennow et al., 2016; Mollayeva et al., 2017). TBI patients are also susceptible to stroke, epilepsy, and Alzheimer\'s disease (Johnson et al., 2010; Liu et al., 2017).

Over 5.3 million Americans suffer lifelong disabilities due to TBI and 1.7 million Americans meet with TBI-associated accidents annually (Gardner and Zafonte, 2016). Approximately 52,000 Americans die annually as a result of TBI ([www.cdc.gov/traumaticbraininjury/data](www.cdc.gov/traumaticbraininjury/data)). As estimated by the World Health Organization, TBI will become the leading cause of death and disability worldwide by the year 2020 (Hyder et al., 2007). In terms of TBI-related mortality, the US 2006--2010 data revealed males had an almost three-fold increased risk of TBI-related death than females, and individuals over the age of 64 years had the highest mortality rates ([www.cdc.gov/traumaticbraininjury/data](www.cdc.gov/traumaticbraininjury/data); Faul and Coronado, 2015). TBI among children aged 0--14 years is also prevalent due to falls (Langlois et al., 2005). The total (direct and indirect) TBI costs in the USA were approximately \$60.43 billion in 2000 (Corso et al., 2006), which has now increased to approximately \$76.5 billion ([www.cdc.gov/traumaticbraininjury/data](www.cdc.gov/traumaticbraininjury/data)). Despite substantial investments in TBI research, the treatment options are limited to manage the sequelae of the injury. The state of TBI science and pharmacotherapy have been thoroughly reviewed recently (Diaz-Arrastia et al., 2014).

Immediately following TBI, the direct trauma and lack of blood flow cause necrotic neuronal death; however, even greater apoptotic neuron loss can occur later from secondary injury caused by hypoxia/ischemia and insults associated with oxidative stress and inflammation (Coles, 2004; Greve and Zink, 2009; Diaz-Arrastia et al., 2014). Focal injury, as a result of TBI, affects not only locomotor function but also cognition, perhaps because damage to brain connectivity is a critical component in the cognitive impairment from TBI. Moreover, cognitive impairment may not be the result of a single event but due to multiple mechanisms originating from secondary injury (Lloyd et al., 2008). The neurorepair process (in the chronic phase) depends on regeneration mechanisms that involve a coordinated integration of angiogenesis, neurogenesis, and remyelination of new and spared axons (Lu et al., 2007). Therapies to increase regeneration activity (angiogenesis, neurogenesis, remyelination) during the chronic phase of TBI therefore hold promise as a treatment strategy for stimulating the recovery of neurological functions.

Approximately 40% of all TBIs are contusions; therefore, animal models of TBI using the focal cortical impact injury (CCI) technique are recognized as physiologically relevant to human TBI (Pennings et al., 1993). The CCI technique was developed by General Motors to model head injuries from automobile accidents and was later adapted for wider experimental use (Lighthall et al., 1989). It reproduces many of the features of brain injuries, including motor deficits, dementia, memory loss, and neuronal loss (Colicos et al., 1996). The severity of injury can be controlled by altering the velocity and depth of the impact and the size of the impact or tip (Dixon et al., 1991). CCI provides an animal model system to evaluate injuries in both the acute and chronic phases. The mechanisms of the injury in the two phases are different and complex. While CCI results in a significant number of necrotic as well as apoptotic neurons in the acute phase, it lacks sufficient regeneration process stimulation (Diaz-Arrastia et al., 2014). Stimulating neurorepair activity by therapeutic modalities, *via* neurotrophic and growth factors, has been shown to improve motor and cognitive functions (Oyesiku et al., 1999; Kim et al., 2001; Wu et al., 2008; Sun et al., 2009). Our studies show that S-nitrosoglutathione (GSNO)-induced mechanisms stabilize hypoxia-inducible factor-1 alpha (HIF-1α) and stimulate the mechanisms of regeneration and functional recovery in TBI (Khan et al., 2016a). Unlike in stroke, the role of HIF-1α in TBI is less understood. While the activity of HIF-1α is increased immediately after TBI, its expression levels are significantly decreased 24 hours following TBI (Ding et al., 2009). Studies from other laboratories have also reported that neurorepair (stimulation of the expression of vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF)) mechanisms in the chronic phase of TBI are dependent on HIF-1α activity (Sen and Sen, 2016; Thelin et al., 2016).

HIF-1α and its regulating enzymes, including prolyl-4-hydroxylases (PHDs), are directly regulated by S-nitrosylation (Metzen et al., 2003), leading to stabilization of HIF-1α and induction of neurorepair mechanisms in the repair phase. S-nitrosylation-mediated stabilization of HIF-1α was also reported to increase angiogenesis and myocardial protection (Lima et al., 2009), indicating a protective role of S-nitrosylated HIF-1α. Therefore, we investigated whether S-nitrosylation-mediated modulation of HIF-1α induces neurorepair, leading to functional recovery in a rat CCI model of TBI.

HIF-1, a nuclear transcription factor, was discovered by Dr. Semenza in 1996 (Semenza, 1996). It was characterized as the master regulator of cellular oxygen homeostasis. It activates the tissue survival pathways by inducing several key enzymes involved in cell metabolism glucose transporter (GLUT), angiogenesis (VEGF, VEGFR1, angiopoietin), and free radical scavenging (heme hydroxylase-1; HO-1) (Ke and Costa, 2006). HIF is a heterodimeric protein composed of α and β subunits. There are three HIF-α isoforms (HIF-1α, HIF-2α and HIF-3α). The beta class includes HIF-1β. HIF-1 is a combination of the HIF-1α (120 kDa) and HIF-1β (91-94 kDa) subunits. The HIF-1β subunit is a constitutively expressed protein, but the expression of the HIF-1α subunit (a cytosolic protein) is largely dependent on oxygen levels. HIF-1α is rapidly up regulated in response to hypoxia and is rapidly degraded upon reoxygenation/reperfusion. Under normoxia, HIF-1α is bound by the von Hippel-Lindau protein (pVHL). pVHL recruits a ubiquitin ligase that targets HIF-1α for the 26S proteasomal degradation. The binding of pVHL is dependent upon hydroxylation of specific proline residues in HIF-1α (pro402 and pro564) by the PHD family of proteins (PHDs), especially HIF-1α-specific PHDs, such as PHD3/PHD2 (please see Ke and Costa, 2006; Harten et al., 2010 for details). These PHD isozymes share maximum homology, and they are implicated in degradation of HIF-1α. PHDs use oxygen as a substrate; therefore, their activity is inhibited under hypoxia. Oxygen can also activate factor-inhibiting HIF (FIH), leading to prevention of the binding of the co-activators p300/CBP, thus down regulating HIF-1-induced transcriptional activity (**[Figure 1](#F1){ref-type="fig"}**). HIF-1α knockout mice show impaired vascular development and embryonic lethality, indicating HIF-1\'s protective role in vascular diseases (Iyer et al., 1998).
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Remarkably, the HIF-1α pathway is involved in both pathological (hypoxia) and neurorepair (normoxia) mechanisms following TBI. The HIF-1α stabilizers/inducers, such as desferrioxamine (an iron chelator approved for haemochromatosis treatment), promote a number of survival pathways, including neuroprotection, angiogenesis and neurotrophins, and reduce brain infarctions when administered pre- or post-stroke (Kasivisvanathan et al., 2011). PHD inhibitors, such as FG-4539, are presently in a phase II anemia trial because of their activity to stabilize HIF-1α by preventing degradation with the ubiquitin proteasome system (Harten et al., 2010). However, inhibition of HIF-1α in the acute injury phase of TBI has also been reported to be neuroprotective (Shenaq et al., 2012; Schaible et al., 2014).

Under normoxic conditions, studies are lacking on direct stabilization of HIF-1α by secondary modification and the induction of consequent protective genes. Nevertheless, S-nitrosylation has been shown to stabilize HIF-1 protein expression and activity in normoxic endothelial cells (Palmer et al., 2000). Later, it was confirmed that, while GSNO stabilizes HIF-1α by S-nitrosylation, reactive nitrogen species (peroxynitrite) destabilize HIF-1α (**[Figure 1](#F1){ref-type="fig"}**) (Wellman et al., 2004). GSNO-mediated stabilization of HIF-1α has been shown to be dependent on PI3K/Akt activity (Carver et al., 2007). A recent study in a mouse model of stroke shows that S-nitrosylation of phosphatase and tensin homolog (PTEN) results in an inhibition of its activity, leading to the activation of Akt (Numajiri et al., 2011). GSNO also activated Akt in a rat model of experimental stroke (Sakakima et al., 2012). Furthermore, GSNO also attenuated PHD activity during normoxia and inhibited proteasomal degradation of HIF-1α (Metzen et al., 2003). S-nitrosylation-mediated stabilization of HIF-1α has been shown to protect against myocardial injury *via* the VEGF/angiogenesis pathway in GSNO reductase (GSNOR) knockout mice (Lima et al., 2009), indicating that HIF-1 is a key player in the regeneration process. Our TBI studies showing that the HIF-1α/VEGF pathway accelerated functional recovery in a 2-week mouse model of TBI *via* S-nitrosylation of HIF-1α further support the neuroreparative role of HIF-1α (Khan et al., 2016a) as depicted in **[Figure 2](#F2){ref-type="fig"}**. S-nitrosylation/GSNO-mediated increased expression HIF-1α and stimulation of neurotrophic factors provide a strong rationale to evaluate the potential of a GSNO-mediated HIF-1α pathway for human therapy in the chronic phase of TBI.

![Schematic showing that exogenously administered GSNO stabilizes HIF-1α *via* S-nitrosylation, leading to the stimulation of neurorepair mediators and functional recovery in TBI.\
GSNO-mediated S-nitrosylation occurs on pVHL, PHD, and HIF-1α, contributing to the inhibition of HIF-1α degradation. S-nitrosylated HIF-1α moves to the nucleus, where it dimerizes with HIF-1β and interacts with P300 and CBP, leading to transcription of neurorepair mediators such as VEGF and BDNF under TBI conditions. Black broken arrows indicate that these mechanisms are not well understood. BDNF: Brain-derived neurotrophic factor; CBP: CREB-binding protein; GSNO: S-nitrosoglutathione; HIF-1: hypoxia-inducible factor 1; PHD: prolyl-4-hydroxylase; pVHL: von Hippel-Lindau protein; SNO: S-nitrosylation; TBI: traumatic brain injury; VEGF: vascular endothelial growth factor.](NRR-12-696-g002){#F2}

GSNO is a natural component of the human body produced by the reaction of nitric oxide (NO) with glutathione (GSH) in the presence of oxygen (Singh et al., 1996). It is sensitive to light, ascorbate, thiols and divalent cations such as Fe^2+^ and Cu^2+^ (Broniowska et al., 2013). GSNO is present in the brain and other organs (Kluge et al., 1997). It is directly involved in cell signaling *via* S-nitrosylation of target proteins, including nuclear factor kappaB (NF-κB), signal transducer and activator of transcription 3 (STAT3), cyclooxygenase-2 (COX-2), caspase-3, calpains, inducible nitric oxide synthase (iNOS), and endothelial NOS (eNOS) and neuronal NOS (nNOS) (Jaffrey et al., 2001; Khan et al., 2005, 2006, 2012, 2016a, b; Kim et al., 2013). Exogenous administration of GSNO (Rassaf et al., 2006) also protects against cardiac ischemic injury (Konorev et al., 1995; Lima et al., 2009), supporting the therapeutic potential of GSNO. Studies have also reported that GSNO inhibits platelet activation in humans (Radomski et al., 1992) and protects both blood-brain barrier integrity and epithelial permeability (Savidge et al., 2007; Khan et al., 2009). Various disease conditions are known to have reduced levels of S-nitrosothiols (-SNO/GSNO) (Snyder et al., 2002; Heiss et al., 2006; Schonhoff et al., 2006) and exogenous administration of GSNO has increased endogenous GSNO and S-NO levels (Khan et al., 2012; Zanini et al., 2012; Hu et al., 2013).

In a microenvironment of TBI, NO released by conventional NO-donors or NO gas itself is anticipated to be inactivated by superoxide, thus forming deleterious peroxynitrite (Singh et al., 2007; Deng-Bryant et al., 2008; Reed et al., 2009). Unlike NO, the disadvantage of inactivation is not associated with the S-nitrosylating agent GSNO (Khan et al., 2006). In addition, S-nitrosylation of cysteine residue (a reversible modification) prevents it from further oxidation to sulfinic and sulfonic acids (an irreversible modification), thereby preventing inactivation of both NO and proteins. The neurorepair effect of GSNO may be mediated by two different mechanisms: 1) S-nitrosylation and 2) maintaining redox by mechanistically reducing the production of oxidants, including peroxynitrite. Such multi-mechanistic functional and therapeutic abilities are not embedded in conventional NO donors as previously reported (Khan et al., 2006), making GSNO a unique candidate to be investigated for the stimulation of functional recovery following TBI.

Several studies showing the efficacy of GSNO in human diseases have been listed by Hornyak et al. (Hornyak et al., 2011). Recently, GSNO was also used in early onset of preeclampsia (Christopher et al.). None of the studies report major or significant side effects associated with the use of GSNO in humans. GSNO-releasing nanoparticles, hydrogel and/or polymers are also used tropically in wound healing and skin diseases (Georgii et al., 2011; Chouake et al., 2012). Microparticles loaded with GSNO have a much longer half-life than free GSNO and show neurovascular protective efficacy in an animal model of embolic stroke (Parent et al., 2015). GSNO-mediated therapeutic effects can also be achieved *via* the inhibition of GSNO reductase (GSNOR) enzyme. GSNOR is the major GSNO-metabolizing enzyme and thus GSNOR knock out mice store GSNO in excess. GSNOR degrades GSNO into ammonia and oxidized glutathione without releasing free NO. Other enzymes, including carbonyl reductase, formaldehyde dehydrogenase and gamma glutamyl transpeptidase also metabolize GSNO, but their activity is not specific toward GSNO (Foster et al., 2009). Pharmacological inhibition of GSNOR has also been shown to improve endothelial functions (Chen et al., 2013), indicating a protective role of GSNO in neurovascular dysfunction. A recent report shows that GSNOR knock out mice behave normally and GSNO invokes its mechanistic effect *via* the mechanisms of trans-S-nitrosylation (Moon et al., 2017). However, another study found GSNOR knock mice having compromised neuro-muscular functions (Montagna et al., 2014). Use of GSNOR inhibitors have been found beneficial in animal models of experimental asthma (Ferrini et al., 2013), allergic airway inflammation (Blonder et al., 2014) and endothelial vasodilatory dysfunction (Chen et al., 2013). These results support the association of beneficial activity with GSNO-mediated mechanisms in several diseases.

Conclusion {#sec1-2}
==========

The potential of GSNO as an HIF-1α stabilization-based therapeutic agent in TBI offers a novel target for further investigation (**[Figure 2](#F2){ref-type="fig"}**). Mechanistically, GSNO invokes its action mainly *via* an S-nitrosylation-based mechanism, a physiological secondary protein modification process. Unlike other chemical therapeutics, GSNO is an endogenous neurorepair-inducing agent and its exogenous administration protects against neurodegenerative disease mechanisms in stroke, spinal cord injury, and TBI. The treatment with GSNO accelerated functional recovery and improved overall outcomes in a comparatively long-term TBI study (Khan et al., 2016a). Furthermore, GSNO\'s administration in humans for other indications resulted in no toxicity or side effects, thus supporting the translational potential of GSNO therapy in TBI. A long term study showing stimulation of neurorepair mechanisms and improvements of neurological functions in humans will determine the overall efficacy and the clinical relevance of GSNO as a rehabilitation therapy in TBI.
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